Market News
Stay updated with the latest market trends, earnings, and economic indicators.
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardt’s newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.
Wockhardt secures US FDA approval for antibiotic Zaynich
Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.
Stock Market Crash News Today Live Updates: Nifty Below 23,800, Sensex Falls 700 Points From Day's High; Ola Electric, Wockhardt Surge up To 17% - NDTV Profit
Stock Market Crash News Today Live Updates: Nifty Below 23,800, Sensex Falls 700 Points From Day's High; Ola Electric, Wockhardt Surge up To 17%NDTV Profit
Wockhardt hits all-time high on CDSCO approval for antibiotic Zaynich
The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime
Breakout stocks: How to trade Ola, GMR Airports, Wockhardt? Analyst decodes
Mayank Jain, market analyst at Share.Market by PhonePe believes that the long-term trend for Ola Electric can change from 'Bearish to Bullish' if the stock manages to sustain above ₹40 consistently.
Supriya Lifescience Ltd leads gainers in 'A' group
Relaxo Footwears Ltd, Wockhardt Ltd, Netweb Technologies India Ltd and Ashapura Minechem Ltd are among the other gainers in the BSE's 'A' group today, 29 May 2026.
Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drug’s potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock extend recent gains despite technically entering overbought territory after a sharp rally.
Wockhardt spurts after India approves breakthrough antibiotic Zaynich
Wockhardt rose 7.47% to Rs 1904 after the company received regulatory approval for its breakthrough antibiotic Zaynich in India.
Wockhardt shares jump 9% after CDSCO approves breakthrough antibiotic Zaynich in India
The drug has been approved for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, as well as infections accompanied by Gram-negative bacteremia.
Wockhardt Shares Surge Over 11% After CDSCO Nod For Zaynich Antibiotic In India
Wockhardt Ltd shares surged over 11%
Wockhardt gets CDSCO nod for Zaynich antibiotic
Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potential against drug-resistant bacteria. This marks a significant step in combating challenging infections.
Wockhardt Ltd rises for third consecutive session
Wockhardt Ltd is quoting at Rs 1739.5, up 2.31% on the day as on 12:49 IST on the NSE. The stock is up 30.09% in last one year as compared to a 3.32% spurt in NIFTY and a 15.48% spurt in the Nifty Pharma index.